Daewoong Therapeutics provides CDO/CRO services based on Korea's best CMC R&D/licensing experience and excellent human resources pool.

CDMO Services powered by Korea’s premier CMC expertise

Since its establishment, Daewoong Therapeutics has successfully undertaken numerous formulation studies and technical transfers for supergenerics, marking incremental advancements in drug development. Our first transferred product, DWRX1004, achieved market approval in April 2022 and generated an impressive 4 million USD in its debut year.

Our team, consisting of chemists with decades of industrial experience, is adept at meeting our clients’ diverse needs. We specialize in a broad spectrum of pharmaceutical areas, ranging from small molecule compounds to peptides, ophthalmic solutions, and long-acting injectables and more. Let us help you guide your product’s journey toward an effective and innovative upgrade.